睿昂基因(688217.SH):公司T790M試劑盒產品(數字PCR)已經完成體系考核 正處於補充材料階段
格隆匯4月28日丨有投資者向睿昂基因(688217.SH)提問:請問公司研發的人EGFR基因T790M突變檢測試劑盒有什麼進展嗎?
睿昂基因回覆:在實體瘤領域,公司採用微滴式數字PCR方法研發的人EGFR基因T790M突變檢測試劑盒,在阿斯利康進行的多家供應商腫瘤外周血富集檢測T790M突變試劑盒評選中獲得滿分評價,且其檢測精度達到0.05%,達到國際先進水平。目前公司T790M試劑盒產品(數字PCR)已經完成體系考核,正處於補充材料階段,未來獲批後,公司將深化同阿斯利康的合作模式,藉助其銷售渠道加速入院。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.